Valeant posts loss on Medicis buyout costs; Cipla hikes offer for Cipla Medpro to $512M;

@FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma

@EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce

> Valeant Pharmaceuticals ($VRX) swung to a loss in the fourth quarter, thanks to charges related to its Medicis Pharmaceutical buyout. Report | Release

> Indian generics maker Cipla hiked its offer for South Africa's Cipla Medpro by 17%, bringing its bid to $512 million. Report

> Lundbeck won European approval for Selincro, a treatment for alcohol dependency that's key to the Danish drugmaker's growth strategy. Report

> Ipsen posted a full-year loss of €29 million ($37.9 million) after pulling out of the hemophilia treatment market. Report

> An Indian court put Cadila Pharmaceuticals on notice after the drugmaker failed to raise employees' salaries as ordered by an industrial tribunal. Report

Biotech News

 @FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech

@JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce

@RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce

> Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article

> Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs. More

> Takeda snags rights to lupus drugs from Seattle upstart in $255M deal. News

Medical Device News

 @FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev

 @MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce

 @DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce

> Medtronic scores CE mark for novel TAVI valve. News

> Sorin commits $5M more to Israeli heart failure device startup, with option to buy. More

> Natus predicts 20% revenue soar in 2013. Article

Vaccines News

> FDA panel endorses quadrivalents, setting stage for new flu market. Article

> Is it too soon to quit on Nabi's nicotine vaccine? More

> Seasonal flu vaccine only 56% effective. Story

> GSK facing competition from Sanofi's 6-in-1 shot. Item

> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report

Pharma Manufacturing News

> Ranbaxy problems overshadow manufacturing expansion. Article

> Qualicaps adds new technology as part of expansion. Item

> FDA warning to Abbey questions quality of API for sterile drugs. Story

> Hospira manufacturing problems arise at an inopportune time. More

And Finally... Autism shares genetic features with four other psychiatric disorders, including bipolar disorder and schizophrenia. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.